Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study
NCT ID: NCT01528514
Last Updated: 2019-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2009-09-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery
NCT07009340
A Registry Study on Serumal Biomarkers About Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.
NCT04107571
Post Coronary Artery Bypass Graft (CABG) Study
NCT00000463
Colchicine in Coronary Artery Bypass Graft (CABG)
NCT02122484
Intraoperative Hemodynamics in CABG
NCT05125315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Curcuminoids
Curcuminoids
Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
Placebo
Placebo
Placebo in capsule form, 4 capsules 4 times/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Curcuminoids
Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
Placebo
Placebo in capsule form, 4 capsules 4 times/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
* patients with cholestatic jaundice (total bilirubin \> 2-fold ULN)
* severe liver disease (AST or ALT \> 3-fold ULN)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wanwarang Wongcharoen, MD.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wanwarang Wongcharoen, MD.
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wanwarang Wongcharoen, MD
Role: PRINCIPAL_INVESTIGATOR
Faculty of Medicine, Chiang Mai University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maharaj Nakorn Chiang Mai hospital
Chiang Mai, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRG5380258
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.